Quarterly report · Q3
9627.TEDINET S100T2A7
Period2023-05-01 → 2024-01-31
Filed2024-03-15
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥296.4bn | 2023-05-01 → 2024-01-31 | Cons. | Net sales |
| Revenue | ¥358.7bn | 2022-05-01 → 2023-04-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥263.9bn | 2022-05-01 → 2023-01-31 | Cons. | Net sales |
| Operating income | ¥14.3bn | 2023-05-01 → 2024-01-31 | Cons. | Operating income |
| Operating income | ¥11.7bn | 2022-05-01 → 2023-01-31 | Cons. | Operating income |
| Ordinary income | ¥15.1bn | 2023-05-01 → 2024-01-31 | Cons. | Ordinary income |
| Ordinary income | ¥17.1bn | 2022-05-01 → 2023-04-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥12.4bn | 2022-05-01 → 2023-01-31 | Cons. | Ordinary income |
| Profit before tax | ¥15.0bn | 2023-05-01 → 2024-01-31 | Cons. | Income before income taxes |
| Profit before tax | ¥12.1bn | 2022-05-01 → 2023-01-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥8.7bn | 2023-05-01 → 2024-01-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥9.2bn | 2022-05-01 → 2023-04-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.6bn | 2022-05-01 → 2023-01-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥8.7bn | 2023-05-01 → 2024-01-31 | Cons. | Profit loss |
| Net income | ¥6.6bn | 2022-05-01 → 2023-01-31 | Cons. | Profit loss |
| Total assets | ¥243.7bn | at 2024-01-31 | Cons. | Assets |
| Total assets | ¥231.8bn | at 2023-04-30 | Cons. | Assets |
| Total assets | ¥229.6bn | at 2023-01-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥110.4bn | at 2024-01-31 | Cons. | Liabilities |
| Total liabilities | ¥105.2bn | at 2023-04-30 | Cons. | Liabilities |
| Net assets / equity | ¥133.3bn | at 2024-01-31 | Cons. | Net assets |
| Net assets / equity | ¥126.5bn | at 2023-04-30 | Cons. | Net assets |
| Net assets / equity | ¥123.7bn | at 2023-01-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥50.1bn | at 2024-01-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥46.8bn | at 2023-04-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥248.51 | 2023-05-01 → 2024-01-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥98.85 | 2023-11-01 → 2024-01-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥262.87 | 2022-05-01 → 2023-04-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥188.7 | 2022-05-01 → 2023-01-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥80.4 | 2022-11-01 → 2023-01-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 54.7% | at 2024-01-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.6% | at 2023-04-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.9% | at 2023-01-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2023-05-01 → 2024-01-31 | ¥8.5bn |
| Otherother segments | revenue external | 2023-05-01 → 2024-01-31 | ¥8.4bn |
| Otherother segments | revenue intersegment | 2023-05-01 → 2024-01-31 | ¥37m |
| Otherother segments | segment ordinary income | 2023-05-01 → 2024-01-31 | −¥80m |
| Reconciling Itemsreconciling | revenue | 2023-05-01 → 2024-01-31 | −¥37m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-05-01 → 2024-01-31 | −¥37m |
| Reconciling Itemsreconciling | segment ordinary income | 2023-05-01 → 2024-01-31 | −¥6.8bn |
| jpcrp040300-q3r_E04896-000Dispensing Pharmacyreportable segment | revenue | 2023-05-01 → 2024-01-31 | ¥265.0bn |
| jpcrp040300-q3r_E04896-000Dispensing Pharmacyreportable segment | revenue external | 2023-05-01 → 2024-01-31 | ¥265.0bn |
| jpcrp040300-q3r_E04896-000Dispensing Pharmacyreportable segment | segment ordinary income | 2023-05-01 → 2024-01-31 | ¥19.7bn |
| jpcrp040300-q3r_E04896-000Drug And Cosmetic Storereportable segment | revenue | 2023-05-01 → 2024-01-31 | ¥22.9bn |
| jpcrp040300-q3r_E04896-000Drug And Cosmetic Storereportable segment | revenue external | 2023-05-01 → 2024-01-31 | ¥22.9bn |
| jpcrp040300-q3r_E04896-000Drug And Cosmetic Storereportable segment | segment ordinary income | 2023-05-01 → 2024-01-31 | ¥2.2bn |
| —segment total | revenue | 2023-05-01 → 2024-01-31 | ¥296.4bn |
| —segment total | revenue external | 2023-05-01 → 2024-01-31 | ¥296.4bn |
| —segment total | revenue intersegment | 2023-05-01 → 2024-01-31 | ¥37m |
| —segment total | segment ordinary income | 2023-05-01 → 2024-01-31 | ¥21.9bn |
| Otherother segments | revenue | 2022-05-01 → 2023-01-31 | ¥8.7bn |
| Otherother segments | revenue external | 2022-05-01 → 2023-01-31 | ¥8.7bn |
| Otherother segments | revenue intersegment | 2022-05-01 → 2023-01-31 | ¥43m |
| Otherother segments | segment ordinary income | 2022-05-01 → 2023-01-31 | −¥2m |
| Reconciling Itemsreconciling | revenue | 2022-05-01 → 2023-01-31 | −¥43m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-05-01 → 2023-01-31 | −¥43m |
| Reconciling Itemsreconciling | segment ordinary income | 2022-05-01 → 2023-01-31 | −¥6.4bn |
| jpcrp040300-q3r_E04896-000Dispensing Pharmacyreportable segment | revenue | 2022-05-01 → 2023-01-31 | ¥236.4bn |
| jpcrp040300-q3r_E04896-000Dispensing Pharmacyreportable segment | revenue external | 2022-05-01 → 2023-01-31 | ¥236.4bn |
| jpcrp040300-q3r_E04896-000Dispensing Pharmacyreportable segment | segment ordinary income | 2022-05-01 → 2023-01-31 | ¥18.0bn |
| jpcrp040300-q3r_E04896-000Drug And Cosmetic Storereportable segment | revenue | 2022-05-01 → 2023-01-31 | ¥18.8bn |
| jpcrp040300-q3r_E04896-000Drug And Cosmetic Storereportable segment | revenue external | 2022-05-01 → 2023-01-31 | ¥18.8bn |
| jpcrp040300-q3r_E04896-000Drug And Cosmetic Storereportable segment | segment ordinary income | 2022-05-01 → 2023-01-31 | ¥737m |
| —segment total | revenue | 2022-05-01 → 2023-01-31 | ¥263.9bn |
| —segment total | revenue external | 2022-05-01 → 2023-01-31 | ¥263.9bn |
| —segment total | revenue intersegment | 2022-05-01 → 2023-01-31 | ¥43m |
| —segment total | segment ordinary income | 2022-05-01 → 2023-01-31 | ¥18.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 375
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)EY新日本有限責任監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)片岡 直彦 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)新木 亘 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 263906000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 296360000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 358742000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 12367000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 15050000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 17064000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 6628000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 8730000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 9234000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 6643000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 8828000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 9446000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 123743000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 133278000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 126546000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 229562000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 243688000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 231750000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 188.70 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 248.51 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 262.87 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | － | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | － | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | － | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.539 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.547 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.546 | |
| Basic earnings loss per share (5-year summary) | Prior1QuarterDuration | 80.40 | |
| Basic earnings loss per share (5-year summary) | CurrentQuarterDuration | 98.85 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 35428212 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 35428212 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 35428212 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 35428212 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 295700 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 35111700 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 351117 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 20812 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 35428212 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 351117 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 295700 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |